COVID-19: Protection of IP for AI tools
01-09-2020
Poptika / Shutterstock.com
Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.
2020 has been a tumultuous year in many respects and the conflation of a pandemic and the impact of the UK’s departure from the EU has profound implications for the life sciences and medical devices industries in the UK and the EU. In this article, we consider how and why these events will have such an effect and how affected businesses may need to prepare for these.
Brexit implications
At 11pm on December 31, 2020, the Brexit transition period will come to an end. At this point, the UK will no longer be required to comply with EU rules and regulations and will no longer be part of the single market and the customs union. In due course, divergence from EU regulations is anticipated, although the extent of such divergence has yet to be seen and continues to be a source of controversy.
Some would like the UK to continue to align itself to the EU standards to facilitate trade with the EU, while others see opportunities to differentiate the UK from the EU. One area where we are already witnessing the beginning of this divergence is in the field of medical devices and medicines.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Brexit, COVID-19, Bird & Bird, life sciences industry, pandemic, MHRA, medical devices, AstraZeneca, Pfizer, BioNTech, vaccine, WHO, FDA, Moderna
